Monoclonal and Polyclonal Antibodies – Why Chickens Beat Mammals for Human TargetsÂ
Antibodies are foundational tools in research, diagnostics, and therapeutics. Traditionally, they are classified into two main types, polyclonal and monoclonal,…
-
-
Bispecific/Multispecific Antibodies: The Common Light Chain and Upper Hand of Humanized Avian Antibodies
Common light chain strategies simplify bispecific IgG assembly across multiple heterodimeric formats by eliminating light chain mispairing and reducing molecular heterogeneity Bispecific…
-
Stay Ahead of the Curve: Fast-Track Antibodies for PD-1, PD-L1 and Other Antigens, With Immunized Libraries
The past few years have brought a wave of promising new targets for the treatment of cancer and inflammatory diseases….
-
BLI vs SPR: Picking the Right Tool for Discovery Campaigns in Biotechs
At Immune Biosolutions, we leverage two core technologies, Bio-Layer Interferometry (BLI) and High-Throughput Surface Plasmon Resonance (HT-SPR), for antibody discovery….
-
Immune Biosolutions announces the appointment of Nicholas Franco as Chairman of its Board of Directors
Immune Biosolutions is pleased to announce the appointment of Nicholas Franco as Chairman of its Board of Directors. Mr. Franco…
-
Safety and efficacy of inhaled IBIO123 for severe COVID-19, new results.
October 6, 2023 Immune Biosolutions is pleased to share the most recent findings from our second Phase 1/2 clinical trial…
-
Immune Biosolutions – A step closer to the first inhaled antibody treatment for COVID-19
SHERBROOKE, QC, Aug. 21, 2023 /CNW/ – Immune Biosolutions, a Canadian biotech company based in Sherbrooke, reached a new milestone in developing the…
-
Neomabs Biotechnologies, a company dedicated to developing new immunotherapies for cancer treatment launches in Montreal
MONTRÉAL, June 7, 2023 – Developing new generations of immunotherapies to treat currently incurable pediatric leukemia is the mission of…
-
Appointment of a new Director to the Board of Directors of Immune Biosolutions Inc.
We are thrilled to welcome a new director to the board of directors of Immune Biosolutions Inc: Mr. Nicholas Franco….
-
Immune Biosolutions reports that its lead immunotherapy product IBIO123 neutralizes 100% of the SARS-CoV-2 variants of concern (VOCs), including Omicron
SHERBROOKE, QC, Jan. 10, 2022 /CNW Telbec/ Immune Biosolutions Inc., a clinical-stage company, is pleased to announce that its leading biological drug…
-
Promising treatment against COVID-19 and its variants: Quebec biotech, Immune Biosolutions begins Phase I clinical trial stages for its inhaled immunotherapy treatment
Immune Biosolutions is pleased to announce the start of Phase I clinical trial for its immunotherapy (IBIO123) treatment, whose antibodies have the potential to neutralize and eliminate COVID-19 and its variants. The treatment has the ability of being administered by inhalation and acts in a highly targeted manner through the lungs to fight the infection at its source.
-
Immune Biosolutions Receives C$13.44 Million to Develop and Biomanufacture its Promising Immunotherapy to Treat COVID-19 and its Variants
SHERBROOKE, QuĂ©bec (March 16, 2021)—Immune Biosolutions, an innovative biotechnology company, receives $13.44M from the Government of Canada’s Strategic Innovation Fund…
